Oncimmune Holdings plc (LON: ONC), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, has announced the appointment to the Senior Leadership Team of Matthew Hall as Group Chief Financial Officer and Andrew Stewart as General Counsel and Company Secretary.
Andrew Millet has stepped down from the Board as Chief Financial Officer, Director and Company Secretary. Andrew will be available to the Company for the next six months to ensure an orderly transition of his CFO responsibilities.
Matthew Hall is a seasoned finance professional with over 25 years’ of corporate finance experience in a number of leading organisations and fast-growing companies. Most recently he was Chief Financial Officer at Tusk Therapeutics and Simbec-Orion Group. Previously, Matthew was Chief Financial Officer at Sphere Medical Holding plc where he was appointed to lead the company’s successful IPO and prior to that was Chief Financial Officer of IS Pharma plc, where he was closely involved in the merger of IS Pharma plc and Sinclair Pharma plc. Matthew is a Chartered Accountant with a degree in Economics.
Andrew Stewart is an international business lawyer with extensive healthcare industry experience. Andrew’s previous role was at Smith & Nephew plc, where he was responsible for leading the legal teams supporting the group’s global M&A efforts and European commercial operations. Before that, he was Chief Counsel, Global Transactions and Corporate at Shire plc. Before joining industry, Andrew spent a number of years in private legal practice, primarily at Clifford Chance. Andrew has extensive experience advising FTSE100 companies and multinationals and has held executive leadership positions. He holds degrees in Law and Science (Biochemistry and Immunology).
Dr Adam Hill, CEO of Oncimmune Holdings plc commented:
“The additions to the Senior Leadership Team we are announcing today will help me drive the delivery of Oncimmune’s strategy to capitalise on the wide range of opportunities presented by our proprietary autoantibody-based platform. Matthew and Andrew both have highly relevant experience and will support the Board in its day-to-day activities as we set about delivering the next chapter of our Company’s strategy over the next three years.
“I would like to thank Andrew Millet for his 15 years of service to Oncimmune. Andrew has been instrumental in supporting Oncimmune’s journey to date, helping the Company through a step change in process and reporting after Oncimmune’s IPO in May 2016. We wish him well for the future as he seeks to spend more time on his portfolio of directorships and outside interests.”
